Feasibility of Shortening 14-day Hybrid Therapy While Maintaining an Excellent Helicobacter pylori Eradication Rate

Helicobacter

Volumn 19, Issue 3, 2014, Pages 207-213

  Wu, Jeng Yih ^a,b,c   Hsu, Ping I ^d   Wu, Deng Chyang ^a,b,e   Graham, David Y ^f   Wang, Wen Ming ^a,b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MUNICIPAL TA TUNG HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

14 day hybrid therapy; Amoxicillin; Clarithromycin; Clinical trial; Helicobacter pylori eradication; Metronidazole

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; METRONIDAZOLE; ANTIINFECTIVE AGENT; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; ADULT; ANOREXIA; ANTIBIOTIC RESISTANCE; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DUODENUM ULCER; ERADICATION THERAPY; FATIGUE; FEASIBILITY STUDY; FEMALE; GASTRITIS; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HYBRID THERAPY; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SELECTION BIAS; STOMACH CANCER; STOMACH ULCER; TASTE DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; ADOLESCENT; AGED; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; HELICOBACTER INFECTIONS; ISOLATION AND PURIFICATION; MIDDLE AGED; PROCEDURES; TIME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; ESOMEPRAZOLE; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; PILOT PROJECTS; PROTON PUMP INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899124358     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12113     Document Type: Article

References (21)

1. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:34-42.
2. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-53.
3. Liou JM, Chen CC, Chen MJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013;381:205-13.
4. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009;104:3069-79; quiz 1080.
5. Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011;8:79-88.
6. Gisbert JP, Calvet X, O'Connor A, Megraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010;44:313-25.
7. Sanchez-Delgado J, Calvet X, Bujanda L, Gisbert JP, Tito L, Castro M. Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice. Am J Gastroenterol 2008;103:2220-3.
8. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011;378:507-14.
9. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014;12:177-86.e3.
10. Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011;16:139-45.
11. Graham DY, Fischbach LA. Letter: the ethics of using inferior regimens in H. pylori randomised trials. Aliment Pharmacol Ther 2012;35:852-4; discussion 8.
12. Graham DY. Helicobacter pylori eradication therapy research: ethical issues and description of results. Clin Gastroenterol Hepatol 2010;8:1032-6.
13. Pounder RE, Talley NJ. Letter: the ethics of using inferior regimens in H. pylori randomised trials - editors's reply. Aliment Pharmacol Ther 2012;35:858.
14. White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ 2011;342:d40.
15. Kwon DH, Dore MP, Kim JJ, Kato M, Lee M, Wu JY, Graham DY. High-level beta-lactam resistance associated with acquired multidrug resistance in Helicobacter pylori. Antimicrob Agents Chemother 2003;47:2169-78.
16. Kwon DH, El-Zaatari FA, Kato M, Osato MS, Reddy R, Yamaoka Y, Graham DY. Analysis of rdxA and involvement of additional genes encoding NAD(P)H flavin oxidoreductase (FrxA) and ferredoxin-like protein (FdxB) in metronidazole resistance of Helicobacter pylori. Antimicrob Agents Chemother 2000;44:2133-42.
17. Osato MS. Antimicrobial susceptibility testing for Helicobacter pylori: sensitivity test results and their clinical relevance. Curr Pharm Des 2000;6:1545-55.
18. Wang WM, Lee SC, Ding HJ, et al. Quantification of Helicobacter pylori infection: simple and rapid 13C-urea breath test in Taiwan. J Gastroenterol 1998;33:330-5.
19. Molina-Infante J, Romano M, Fernandez-Bermejo M, et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 2013;145:121-8.e1.
20. Wu JY, Liou JM, Graham DY. Evidence-based recommendations for successful Helicobacter pylori treatment. Expert Rev Gastroenterol Hepatol 2014;8:21-8.
21. Georgopoulos SD, Xirouchakis E, Martinez-Gonzalez B, Sgouras DN, Spiliadi C, Mentis AF, Laoudi F. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area. Helicobacter 2013;18:459-67.